ReFacto AF

DRUG5 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, Pfizer

Conditions

Hemophilia A

Phase 3

Study Evaluating ReFacto AF in Severe Hemophilia A

CompletedNCT00037544

Wyeth is now a wholly owned subsidiary of PfizerHemophilia A

End: 2004-08-31Updated: 2008-04-22

Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A

CompletedNCT00038935

Wyeth is now a wholly owned subsidiary of PfizerHemophilia A

End: 2003-02-28Updated: 2008-04-22

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

CompletedNCT00141843

Wyeth is now a wholly owned subsidiary of PfizerHemophilia A

Start: 2005-07-31End: 2006-11-30Target: 100Updated: 2008-04-22

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

CompletedNCT00243659

Wyeth is now a wholly owned subsidiary of PfizerHemophilia A

Start: 2006-04-30End: 2008-06-30Updated: 2011-06-03

Unknown Phase

Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis

WithdrawnNCT02718677

PfizerHemophilia A

Start: 2019-09-01End: 2022-01-01Updated: 2020-11-16